STI-6129

· Sorrento Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for STI-6129, covering 2023-01-17 to 2023-01-17. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis [Phase 1, Phase 2]

See pricing